STAT
DECEMBER 1, 2023
In Ukraine, a little bit of good news can go a long way, and the lifesaving work being done as a result of the President’s Emergency Plan for AIDS Relief (PEPFAR) has been a rare but reliable source of good news. That’s why the U.S. Congress’ delay in reauthorizing this program has been so difficult to hear about. Much has been written about the impact of PEPFAR since its inception in 2003.
PharmaVoice
DECEMBER 1, 2023
IDEA Pharma just released its Digital Innovation Index. Here are the top companies they identified and some of the standout advances the industry made.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
STAT
DECEMBER 1, 2023
When Jennifer Case was living in Los Angeles in her early 30s, she was hospitalized 11 times. She had been born with two rare heart abnormalities, Ebstein anomaly and Wolff-Parkinson-White syndrome. Her parents were told that she probably wouldn’t live.
The Pharmacist
DECEMBER 1, 2023
Drafts of the 23 patient group directions (PGDs) and one protocol for the Pharmacy First service have now been published by NHS England. This follows the release earlier in the week of service specifications and the clinical pathways for the seven common conditions included in the scheme – uncomplicated urinary tract infection (UTI) in women, […] The post NHS England releases PGDs for Pharmacy First service appeared first on The Pharmacist.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
STAT
DECEMBER 1, 2023
Children with drug-resistant epilepsy who are Black or insured through Medicaid may be less likely than white and privately insured patients to receive surgical treatments that can end or minimize their seizures and extend their lives, according to new research being presented Monday at the American Epilepsy Society’s annual meeting in Orlando, Fla.
Safe Biologics
DECEMBER 1, 2023
From November 12-14, ASBM exhibited at Booth #2612 at ACR Convergence 2023 in San Diego, CA. ACR Convergence is hosted annually by the American College of Rheumatology and is considered the premier meeting for rheumatology professionals globally. ASBM was represented at the booth by Executive Director Michael Reilly, Advisory Board Chair Philip Schneider, and Programs Director Ray Patnaude.
Pharmacist Digest brings together the best content for pharmacists from the widest variety of industry thought leaders.
PharmExec
DECEMBER 1, 2023
Artificial intelligence is making it quicker to get drug candidates to the clinic, but it isn’t addressing the fundamental need to marry the right candidate and the right target to the right disease.
STAT
DECEMBER 1, 2023
After weeks of anticipation, the U.S. Supreme Court on Monday will hear arguments to decide the fate of a controversial bankruptcy deal in which the owners of Purdue Pharma would contribute up to $6 billion in exchange for immunity from further lawsuits. The company was accused of downplaying the risks of OxyContin and improperly persuading physicians to prescribe the addictive painkiller.
The Pharmacist
DECEMBER 1, 2023
New regulatory measures tightening the rules around valproate prescribing are set to come into force from January 2024, and the Medicines and Healthcare products Regulatory Agency (MHRA) is urging healthcare organisations to adequately prepare. From the new year, the first phase of the new measures will curb the use of valproate in new male or […] The post Plan now for upcoming valproate prescribing rule changes, instructs MHRA appeared first on The Pharmacist.
STAT
DECEMBER 1, 2023
One of the hardest parts about getting an X-ray or a CT scan is the wait. Sometimes it takes days, or even weeks, for medical imaging results to be analyzed by a radiologist, transferred to a primary doctor, and then delivered to the patient — good news or bad. Today, that hand-wringing delay has been nearly eliminated. In 2021, provisions from the 21st Century Cures Act kicked in that require health centers to provide patients with access to their health information on request — i
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
The Pharmacist
DECEMBER 1, 2023
Pharmacists can now initiate oral contraception and trained members of the pharmacy team can deliver blood pressure checks, with the expansion of the Pharmacy Contraception Service and the Hypertension Case-Finding Service coming into force from today (1 December 2023). As well as initiating oral contraception, pharmacists can continue to provide ongoing management of oral contraception […] The post Expanded contraception and hypertension pharmacy services go live appeared first on The Pha
STAT
DECEMBER 1, 2023
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Today we talk about Pfizer’s obesity woes, how J&J is leaning heavily into artificial intelligence, chat about how ADCs are having a heyday, and ponder the zombie microcap.
Pharmaceutical Commerce
DECEMBER 1, 2023
In clinical trials, Keytruda plus Padcev lowered the risk of disease progression or death by 55% compared with chemotherapy in adult patients with locally advanced or metastatic urothelial carcinoma.
STAT
DECEMBER 1, 2023
Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others. That’s right. Send us your changes, and we’ll find a home for them. Don’t be shy. Everyone wants to know who is coming and going. And here is our regular feature in which we highlight a different person each week.
European Pharmaceutical Review
DECEMBER 1, 2023
AbbVie has agreed to acquire ImmunoGen and its first-in-class antibody-drug conjugate (ADC) ELAHERE ® (mirvetuximab soravtansine-gynx), for a total of approximately $10.1 billion. The antibody-drug conjugate is the first to be approved for platinum-resistant ovarian cancer (PROC) and show meaningful survival benefit for this form of the disease. As a folate receptor alpha (FRα) with a maytansinoid payload DM4, a potent tubulin inhibitor, the biologic medicine offers expansion opportunities in e
STAT
DECEMBER 1, 2023
Editor’s note: A livestream of the event will be embedded below at 1 p.m. ET. After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.
Pharma Times
DECEMBER 1, 2023
Every year, over 44,000 men are diagnosed with prostate cancer in England - News - PharmaTimes
STAT
DECEMBER 1, 2023
And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is rather modest. We plan to promenade with the official mascots, tidy up the leafy grounds, and maybe have a listening party with Mrs. Pharmalot. The rotation will likely include this , this , this and this.
BioPharma Dive
DECEMBER 1, 2023
The EMA's safety committee has more questions for makers of the in-demand therapies as it reviews whether the drugs are linked to the risk of suicidal thoughts.
Putting Patients First Blog
DECEMBER 1, 2023
Celebrating Creativity and Resilience: EveryLife Foundation’s Rare Artist Program December 1, 2023 By: Stephanie Riordan, Director of Patient Programs, EveryLife Foundation for Rare Diseases In the heart of every challenge lies a unique opportunity for expression and empowerment. At the EveryLife Foundation for Rare Diseases, we firmly believe in the transformative power of art, especially in the lives of those affected by rare diseases.
Board Vitals - Pharmacist
DECEMBER 1, 2023
With 2024 rapidly approaching, there comes the question of New Year’s Resolutions. Are they to be made or ignored? Many physicians use them to refocus their efforts on meaningful initiatives. Under the guise of a new year’s resolution, some clinicians take the opportunity to remind influencers and stakeholders of efforts that need to be redoubled for the benefit of patients and patient care.
Pharma Times
DECEMBER 1, 2023
Every year, around 55,000 women in the UK are diagnosed with the condition - News - PharmaTimes
pharmaphorum
DECEMBER 1, 2023
AstraZeneca has decided to abandon two phase 3 trials of its drug to reduce high levels of potassium in the blood (hyperkalaemia) – Lokelma – in patients with kidney disease. The STABILIZE-CKD and DIALIZE-Outcomes studies – part of AZ’s CRYSTALIZE programme for the drug – have been shelved because patients were being enrolled into them more slowly than hoped for, and clinical events were occurring at a lower rate than expected.
European Pharmaceutical Review
DECEMBER 1, 2023
Since its introduction in 1980, capillary electrophoresis (CE) has been one of the most powerful techniques applicable as a choice method in the biopharmaceutical industry for the characterisation and quality control (QC) testing of biomolecules such as proteins, peptides as well as monoclonal antibodies (mAbs) and high molecular weight polysaccharides. 1 In addition to the intrinsic advantages of CE, such as high separation efficiency, high resolution, low sample volume requirements, short sepa
Pharmaceutical Technology
DECEMBER 1, 2023
Hot on the heels of the designation, Orchard Therapeutics is pressing ahead with a multi-centre trial for the candidate with a start date in December.
European Pharmaceutical Review
DECEMBER 1, 2023
A new report by the Committee of Experts on minimising the public health risks posed by falsified medical products and related crimes (CD-P-PH/CMED) shares insight on how authorities perceive and address the falsification of medical devices. The report details findings from survey completed by 21 of the 46 Council of Europe member states on counterfeit medical devices.
Express Pharma
DECEMBER 1, 2023
Lupin announced the launch of Turqoz (Norgestrel and Ethinyl Estradiol) Tablets USP, 0.3 mg/0.03 mg, after having received an approval from the United States Food and Drug Administration (US FDA). Turqoz (Norgestrel and Ethinyl Estradiol) Tablets USP, 0.3 mg/0.03 mg is the generic equivalent of Lo/Ovral-28 (Norgestrel and Ethinyl Estradiol) Tablets, 0.3 mg/0.03 mg of Wyeth Pharmaceuticals LLC and is a contraceptive drug indicated to prevent pregnancy.
European Pharmaceutical Review
DECEMBER 1, 2023
During CPHI Barcelona, EPR Editor Caroline Peachey asked Anil Kane, Global Head of Technical & Scientific Affairs, Pharma Services, at Thermo Fisher Scientific about the dynamic landscape of pharmaceutical drug development. Dr Kane leads a team of subject matter experts at Thermo Fisher, covering drug products in both sterile injectable dosage and oral solid dosage forms.
Express Pharma
DECEMBER 1, 2023
Syngene International announced the conclusion of the acquisition of a multi-modal biologics manufacturing facility from Stelis Biopharma as announced on July 4, 2023. The acquisition of the ‘Unit 3’ biologics manufacturing facility was concluded at a revised gross value of Rs 617 crores adjusted from the earlier gross value of Rs 702 crores. The reduction in gross value reflects the retention of certain equipment not currently installed in the facility by Stelis Biopharma.
Pharmaceutical Technology
DECEMBER 1, 2023
The SMC and NICE have recommended the use of AstraZeneca’s durvalumab to treat advanced biliary tract cancers in England and Scotland.
Express Pharma
DECEMBER 1, 2023
How does Körber contribute to safe and efficient processes in the manufacture, inspection, and packaging of pharma products? Can you share some examples of innovative solutions or technologies that your company has developed for the pharma industry? In the dynamic landscape of pharma manufacturing, we are standing as a beacon for safe and efficient processes.
Pharmaceutical Technology
DECEMBER 1, 2023
Biocon subsidiary Biocon Biologics has successfully integrated Viatris' biosimilars business in 31 countries in Europe.
The Pharmacist
DECEMBER 1, 2023
There are currently ‘no plans’ to add to the seven common conditions covered by the incoming Pharmacy First service, the government has confirmed. Responding to a series of written questions from Peter Dowd, Labour MP for Bootle, the new pharmacy minister Andrea Leadsom outlined details of the service, listing the seven conditions – sinusitis, sore […] The post Currently ‘no plans’ to expand Pharmacy First common conditions appeared first on The Pharmacist.
Pharmaceutical Technology
DECEMBER 1, 2023
Partnership deals involving psychedelic drugs saw a 500% growth in total deal volume from 2019 to 2023 year-to-date (YTD).
pharmaphorum
DECEMBER 1, 2023
How to advance more late-stage neuroscience drugs to regulatory approval Mike.
Expert insights. Personalized for you.
355 
Let's personalize your content